Cargando…

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons

In 2016, the WHO announced a plan to eliminate viral hepatitis as a public health threat by 2030. In this narrative review, experts from Bulgaria, Croatia, the Czech Republic, Hungary, Latvia, Lithuania, Poland and Slovakia assessed the feasibility of achieving the WHO 2030 target for HCV infections...

Descripción completa

Detalles Bibliográficos
Autores principales:	Flisiak, Robert, Zarębska-Michaluk, Dorota, Ciupkeviciene, Egle, Drazilova, Sylvia, Frankova, Sona, Grgurevic, Ivica, Hunyady, Bela, Jarcuska, Peter, Kupčinskas, Limas, Makara, Michael, Saulite-Vanaga, Gunita, Simonova, Marieta, Sperl, Jan, Tolmane, Ieva, Vince, Adriana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952509/ https://www.ncbi.nlm.nih.gov/pubmed/35336889 http://dx.doi.org/10.3390/v14030482

Ejemplares similares

How close are we to hepatitis C virus elimination in Central Europe?
por: Flisiak, Robert, et al.
Publicado: (2020)

Genotype Distribution and Characteristics of Chronic Hepatitis C Infection in Estonia, Latvia, Lithuania, and Ukraine: The RESPOND-C Study
por: Jančorienė, Ligita, et al.
Publicado: (2023)

Changes in the Seroprevalence of Helicobacter pylori among the Lithuanian Medical Students over the Last 25 Years and Its Relation to Dyspeptic Symptoms
por: Jonaityte, Ieva Renata, et al.
Publicado: (2021)

Hepatitis C Virus Epidemiology in Lithuania: Situation before Introduction of the National Screening Programme
por: Ciupkeviciene, Egle, et al.
Publicado: (2022)

Perspectives of hepatitis C virus (HCV) elimination in Poland
por: Flisiak, Robert, et al.
Publicado: (2019)

Early oral antiviral use in patients hospitalised with COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

IgG4-Related Sclerosing Cholangitis: Rarely Diagnosed, but not a Rare Disease
por: Drazilova, Sylvia, et al.
Publicado: (2021)

Ways to Eliminate Viral Hepatitis as a Global Health Threat
por: Flisiak, Robert, et al.
Publicado: (2022)

Updates in Management of SARS-CoV-2 Infection
por: Flisiak, Robert, et al.
Publicado: (2022)

Hepatitis C microelimination among people living with HIV in Taiwan
por: Chen, Guan-Jhou, et al.
Publicado: (2022)

R0 Liver Resection should be a First-line Treatment for Selected Patients with Intermediate Hepatocellular Cancer
por: Janicko, Martin, et al.
Publicado: (2023)

COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Predictors of Significant Liver Fibrosis in People with Chronic Hepatitis C Who Inject Drugs in the Czech Republic
por: Frankova, Sona, et al.
Publicado: (2023)

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C
por: Brzdęk, Michał, et al.
Publicado: (2023)

Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy
por: Drazilova, Sylvia, et al.
Publicado: (2018)

The Epidemiology of Primary Biliary Cholangitis in European Countries: A Systematic Review and Meta-Analysis
por: Gazda, Jakub, et al.
Publicado: (2021)

Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
por: Sperl, Jan, et al.
Publicado: (2017)

Therapy of chronic hepatitis C in people who inject drugs: focus on adherence
por: Frankova, Sona, et al.
Publicado: (2021)

Molecular Alterations in Gastric Intestinal Metaplasia
por: Jonaitis, Paulius, et al.
Publicado: (2021)

Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures
por: Flisiak, Robert, et al.
Publicado: (2021)

Viral Hepatitis C New Microelimination Pathways Objective: Psychiatric Communities HCV Free
por: Fiore, Vito, et al.
Publicado: (2022)

Evaluation of hepatic fibrosis – access to non-invasive methods, national practice/guidelines in Central Europe
por: Jarcuska, Peter, et al.
Publicado: (2016)

Toward microelimination of hepatitis C and HIV coinfection in NHS Tayside, Scotland: Real‐world outcomes
por: Byrne, Christopher, et al.
Publicado: (2020)

Model of Care for Microelimination of Hepatitis C Virus Infection among People Who Inject Drugs
por: Foschi, Francesco Giuseppe, et al.
Publicado: (2021)

Retrieval of lost patients in the system for hepatitis C microelimination: a single-center retrospective study
por: Yen, Hsu-Heng, et al.
Publicado: (2021)

Changing Epidemiological Patterns of Infection and Mortality Due to Hepatitis C Virus in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Trends of infections and mortality due to hepatitis B virus (2005-2022) and the potential impact of the COVID-19 pandemic: a population-based study in Poland
por: Genowska, Agnieszka, et al.
Publicado: (2023)

Viral hepatitis C treatment shortening – what is the limit?
por: Zarębska-Michaluk, Dorota
Publicado: (2019)

Genotype 3-hepatitis C virus’ last line of defense
por: Zarębska-Michaluk, Dorota
Publicado: (2021)

1235. Anti-HCV Prevalence and Associated Risk Factors in Patients of Psychiatry Hospitals in Latvia
por: Tolmane, Ieva, et al.
Publicado: (2022)

Effect of COVID-19 on Anti-S Antibody Response in Healthcare Workers Six Months Post-Vaccination
por: Flisiak, Robert, et al.
Publicado: (2021)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Microelimination of Chronic Hepatitis C by Universal Screening Plus Direct-Acting Antivirals for Incarcerated Persons in Taiwan
por: Yang, Tsung-Hua, et al.
Publicado: (2020)

Outcomes of Real-World Integrated HCV Microelimination for People Who Inject Drugs: An expansion of the Punjab Model.
por: Dhiman, Radha K., et al.
Publicado: (2021)

USP18 downregulation in peripheral blood mononuclear cells predicts nonresponse to interferon-based triple therapy in patients with chronic hepatitis C, genotype 1: a pilot study
por: Frankova, Sona, et al.
Publicado: (2015)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

External Validation of UDCA Response Score in Slovak and Croatian Patients with Primary Biliary Cholangitis
por: Gazda, Jakub, et al.
Publicado: (2021)

What is needed to achieve HCV microelimination among HIV-infected populations in Andalusia, Spain: a modeling analysis
por: Skaathun, Britt, et al.
Publicado: (2020)

HCV microelimination in harm reduction centres has benefits beyond HCV cure but is hampered by high reinfection rates
por: Lens, Sabela, et al.
Publicado: (2022)

Epidemiological Modeling of the Impact of Public Health Policies on Hepatitis C: Protocol for a Gamification Tool Targeting Microelimination
por: Baptista-Leite, Ricardo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7vdae456c3u9fqag5lh70ut8m6